|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1998-2-2
|
|
pubmed:abstractText |
The aim of this study was to define the clinical relevance of functional biomarkers, prospectively assessed in a randomized clinical protocol, in patients with Stage III-IV epithelial ovarian cancer. The protocol compared cisplatin with polychemotherapy that included cisplatin and cyclophosphamide.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/DNA,
http://linkedlifedata.com/resource/pubmed/chemical/GSTP1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Glutathione S-Transferase pi,
http://linkedlifedata.com/resource/pubmed/chemical/Glutathione Transferase,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals,
http://linkedlifedata.com/resource/pubmed/chemical/Thymidine,
http://linkedlifedata.com/resource/pubmed/chemical/Tritium,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
82
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
159-67
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9428493-Aged,
pubmed-meshheading:9428493-Antineoplastic Agents,
pubmed-meshheading:9428493-Antineoplastic Agents, Alkylating,
pubmed-meshheading:9428493-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9428493-Carcinoma,
pubmed-meshheading:9428493-Cell Division,
pubmed-meshheading:9428493-Cisplatin,
pubmed-meshheading:9428493-Cyclophosphamide,
pubmed-meshheading:9428493-DNA,
pubmed-meshheading:9428493-Female,
pubmed-meshheading:9428493-Flow Cytometry,
pubmed-meshheading:9428493-Forecasting,
pubmed-meshheading:9428493-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:9428493-Glutathione S-Transferase pi,
pubmed-meshheading:9428493-Glutathione Transferase,
pubmed-meshheading:9428493-Humans,
pubmed-meshheading:9428493-Immunohistochemistry,
pubmed-meshheading:9428493-Isoenzymes,
pubmed-meshheading:9428493-Neoplasm, Residual,
pubmed-meshheading:9428493-Neoplasm Invasiveness,
pubmed-meshheading:9428493-Neoplasm Staging,
pubmed-meshheading:9428493-Ovarian Neoplasms,
pubmed-meshheading:9428493-Ploidies,
pubmed-meshheading:9428493-Prospective Studies,
pubmed-meshheading:9428493-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:9428493-Radiopharmaceuticals,
pubmed-meshheading:9428493-Remission Induction,
pubmed-meshheading:9428493-Survival Rate,
pubmed-meshheading:9428493-Thymidine,
pubmed-meshheading:9428493-Treatment Outcome,
pubmed-meshheading:9428493-Tritium,
pubmed-meshheading:9428493-Tumor Markers, Biological,
pubmed-meshheading:9428493-Tumor Suppressor Protein p53
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
|
|
pubmed:affiliation |
Oncologia Sperimentale C, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
